These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 9239805)

  • 1. Effect of activated charcoal on rifampicin absorption in man.
    Orisakwe OE; Dioka CE; Okpogba AN; Orish CN; Ofoefule SI
    Tokai J Exp Clin Med; 1996 Feb; 21(1):51-4. PubMed ID: 9239805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary excretion of rifampicin in the presence of ciprofloxacin.
    Orisakwe OE; Afonne OJ; Agbasi PU; Ofoefule SI
    Am J Ther; 2004; 11(3):171-4. PubMed ID: 15133531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pefloxacin on the urinary excretion of rifampicin.
    Orisakwe OE; Agbasi PU; Ofoefule SI; Ilondu NA; Afonne OJ; Anusiem CA; Ilo CE; Maduka SO
    Am J Ther; 2004; 11(1):13-6. PubMed ID: 14704591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of kaolin-pectin and activated charcoal for inhibition of aspirin absorption.
    Juhl RP
    Am J Hosp Pharm; 1979 Aug; 36(8):1097-8. PubMed ID: 484570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations.
    Pillai G; Ellard GA; Smith PJ; Fourie PB
    Int J Tuberc Lung Dis; 2001 Aug; 5(8):691-5. PubMed ID: 11495257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality assurance: protocol for assessing the rifampicin bioavailability of combined formulations in healthy volunteers.
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S284-5. PubMed ID: 10593705
    [No Abstract]   [Full Text] [Related]  

  • 7. Disposition of rifampicin following intranasal and oral administration.
    Mamidi NV; Prabhakar MC; Krishna DR
    Indian J Lepr; 1996; 68(2):149-53. PubMed ID: 8835583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of activated charcoal on the bioavailability of piroxicam in man.
    Laufen H; Leitold M
    Int J Clin Pharmacol Ther Toxicol; 1986 Jan; 24(1):48-52. PubMed ID: 3957490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of activated charcoal on diethylcarbamazine absorption in humans.
    Orisakwe OE; Ilondu ND; Afonne OJ; Ofoefule SI; Orish CN; Agbasi PU
    Am J Ther; 2001; 8(1):7-9. PubMed ID: 11304652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acceleration of body clearance of diethylCarbamazine by oral activated charcoal.
    Orisakwe OE; Ilondu NA; Afonne OJ; Ofoefule SI; Orish CN
    Pharmacol Res; 2000 Aug; 42(2):167-70. PubMed ID: 10887047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the adsorption capacities of an activated-charcoal--yogurt mixture versus activated-charcoal--water slurry in vivo and in vitro.
    Hoegberg LC; Christophersen AB; Christensen HR; Angelo HR
    Clin Toxicol (Phila); 2005; 43(4):269-75. PubMed ID: 16035203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acceleration of the body clearance of phenobarbital by oral activated charcoal.
    Berg MJ; Berlinger WG; Goldberg MJ; Spector R; Johnson GF
    N Engl J Med; 1982 Sep; 307(11):642-4. PubMed ID: 7050705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of activated charcoal on ethanol blood levels in dogs.
    North DS; Thompson JD; Peterson CD
    Am J Hosp Pharm; 1981 Jun; 38(6):864-6. PubMed ID: 7246560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of activated charcoal on acetaminophen absorption.
    Levy G; Houston JB
    Pediatrics; 1976 Sep; 58(3):432-5. PubMed ID: 958771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs.
    Lapatto-Reiniluoto O; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 2001 Sep; 70(3):255-60. PubMed ID: 11557913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of activated charcoal administration on acetylcysteine serum levels in humans.
    North DS; Peterson RG; Krenzelok EP
    Am J Hosp Pharm; 1981 Jul; 38(7):1022-4. PubMed ID: 7258201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evaluation of rifampicin bioavailabilities of fixed-dose combinations of anti-tuberculosis drugs: procedures for ensuring laboratory proficiency.
    Ellard GA
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S322-4; discussion S351-2. PubMed ID: 10593711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of activated charcoal and magnesium citrate in the prevention of aspirin absorption in humans.
    Easom JM; Caraccio TR; Lovejoy FH
    Clin Pharm; 1982; 1(2):154-6. PubMed ID: 7185512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics of oral rifampicin in AIDS patients.
    Jaruratanasirikul S
    J Med Assoc Thai; 1998 Jan; 81(1):25-8. PubMed ID: 9470318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic profile of a new 3-azinomethyl rifamycin (SPA-S-565) in volunteers as compared with conventional rifampicin.
    Kelkar MS; Saraf AP; Bakhle DS; Nazare V; Ajay S; Hegde S; Lal HM; Cooverji ND; Bruzzese T
    Int J Clin Pharmacol Res; 1998; 18(3):137-43. PubMed ID: 9825270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.